Our aim has always been to push the boundaries of what technology is able to produce, and we are proud to hold a proprietary technology, named ESiNAR-X®, that gives us a unique advantage compared to the rest of the industry. The platform covers unconventional structural design of oligonucleotide-based inhibitors to significantly improve their characteristics in many ways.

The inhibitors based on the ESiNAR-X® platform show:

  • Exceptional specificity

    do not interfere with homologous RNA off-targets

  • Spontaneous cellular uptake

    less frequent and smaller doses can be applied

  • Unprecedented safety

    preclinical studies showed excellent tolerability

  • Exclusive selectivity

    trigger biologic effects only in target RNA-containing cells

  • Remarkable therapeutic efficacy

    reduce target RNA levels down to even 0%

  • High versatility

    fully adaptable to different target RNAs

The progressiveness of the ESiNAR-X® platform is underlined by its theoretical applicability to any diagnosis with a known genetic causality and/or unmet need. The already shown unmatched accuracy in target recognition resulting in the fascinating possibility of eliminating off-target related side effects may facilitate the implementation of this platform not only in clinical practice, but also for research and technology purposes.

Revolutionary improvement in cellular uptake

Spontaneous internalization
  • Fibroblasts
  • Mesenchymal stem cells
Mesenchymal stem cells
error: Content is protected !!